TrialMalaria journal2025

Safety, tolerability, and efficacy of high versus low-dose, short versus long-course daily primaquine for the radical cure of uncomplicated Plasmodium vivax malaria in children under 15 years of age: an open-label, non-inferiority, randomized controlled trial (CHILDPRIM).

Ana Luisa O Pacheco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.